Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People Aged 2 Years and Above

NCT06044077 is registered in ClinicalTrials.gov with Aimei Vacin BioPharm (Zhejiang) Co., Ltd. as lead sponsor.

NCT NCT06044077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06044077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People Aged 2 Years and Above
Lead sponsor
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
September 8, 2023
Completion date
July 31, 2029
Enrollment
1,920 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pneumococcal disease